CA3218977A1 - A plurality of tasquinimod particles and use thereof - Google Patents

A plurality of tasquinimod particles and use thereof Download PDF

Info

Publication number
CA3218977A1
CA3218977A1 CA3218977A CA3218977A CA3218977A1 CA 3218977 A1 CA3218977 A1 CA 3218977A1 CA 3218977 A CA3218977 A CA 3218977A CA 3218977 A CA3218977 A CA 3218977A CA 3218977 A1 CA3218977 A1 CA 3218977A1
Authority
CA
Canada
Prior art keywords
range
particles
cancer
tasquinimod
dosage unit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3218977A
Other languages
English (en)
French (fr)
Inventor
Hans Wannman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Active Biotech AB
Original Assignee
Active Biotech AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech AB filed Critical Active Biotech AB
Publication of CA3218977A1 publication Critical patent/CA3218977A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Powder Metallurgy (AREA)
CA3218977A 2021-05-25 2022-05-23 A plurality of tasquinimod particles and use thereof Pending CA3218977A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21175623.4 2021-05-25
EP21175623 2021-05-25
PCT/EP2022/063887 WO2022248401A1 (en) 2021-05-25 2022-05-23 A plurality of tasquinimod particles and use thereof

Publications (1)

Publication Number Publication Date
CA3218977A1 true CA3218977A1 (en) 2022-12-01

Family

ID=76098832

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3218977A Pending CA3218977A1 (en) 2021-05-25 2022-05-23 A plurality of tasquinimod particles and use thereof

Country Status (14)

Country Link
US (2) US12485095B2 (enExample)
EP (1) EP4346773B1 (enExample)
JP (1) JP7874664B2 (enExample)
KR (1) KR20240012436A (enExample)
CN (1) CN117295492A (enExample)
AU (1) AU2022281056A1 (enExample)
BR (1) BR112023023715A2 (enExample)
CA (1) CA3218977A1 (enExample)
ES (1) ES3048983T3 (enExample)
IL (1) IL308542A (enExample)
MX (1) MX2023013301A (enExample)
PL (1) PL4346773T3 (enExample)
WO (1) WO2022248401A1 (enExample)
ZA (1) ZA202311594B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025228998A1 (en) * 2024-04-30 2025-11-06 Institut National de la Santé et de la Recherche Médicale Use of hdac4 inhibitors for the treatment of melanoma

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
SE9801474D0 (sv) 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
SE9802549D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
SE0002320D0 (sv) 1999-10-25 2000-06-21 Active Biotech Ab Malignant tumors
SE0201778D0 (sv) 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
CN104016951B (zh) * 2010-03-19 2016-07-13 北京强新生物科技有限公司 靶向癌症干细胞的化合物和组合物
WO2012004338A1 (en) 2010-07-09 2012-01-12 Active Biotech Ab Method for manufacturing of quinoline-3-carboxamides
EP2537517A1 (en) 2011-06-22 2012-12-26 Active Biotech AB Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
TWI686212B (zh) * 2013-03-15 2020-03-01 阿聯商太陽法瑪全球有限公司 醋酸阿比特龍配方
WO2015160696A1 (en) 2014-04-14 2015-10-22 Yale University Compositions and methods of inhibiting histone deacetylases
EP3041472B1 (en) 2014-09-23 2017-02-01 Active Biotech AB Quinoline carboxamides for use in the treatment of multiple myeloma
BR112017009854B1 (pt) * 2014-11-19 2022-08-23 Active Biotech Ab Uso do composto 4-hidroxi-5-metoxi-n,1-dimetil-2-oxo-n-[4-(trifluorometil)fenil]-1,2-dihidroquinolina-3-carboxamida (tasquinimod) ou um sal farmaceuticamente aceitável do mesmo para o tratamento de leucemia
EP3067062A1 (en) 2015-03-13 2016-09-14 Ipsen Pharma S.A.S. Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament
WO2018105943A1 (ko) 2016-12-07 2018-06-14 순천향대학교 산학협력단 폐섬유증 또는 천식의 치료 또는 완화용 약학 조성물
WO2018208993A1 (en) * 2017-05-09 2018-11-15 Dignity Health Drug delivery composition and method of fabrication
US20230293512A1 (en) 2020-07-23 2023-09-21 Erasmus University Medical Center Rotterdam S100 proteins as novel therapeutic targets in myeloproliferative neoplasms
WO2022152902A1 (en) 2021-01-18 2022-07-21 Active Biotech Ab Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome

Also Published As

Publication number Publication date
EP4346773B1 (en) 2025-07-02
US20260076908A1 (en) 2026-03-19
ZA202311594B (en) 2025-04-30
ES3048983T3 (en) 2025-12-12
JP7874664B2 (ja) 2026-06-16
US20240285532A1 (en) 2024-08-29
KR20240012436A (ko) 2024-01-29
JP2024520307A (ja) 2024-05-24
BR112023023715A2 (pt) 2024-02-20
PL4346773T3 (pl) 2025-11-03
MX2023013301A (es) 2023-12-04
AU2022281056A1 (en) 2023-11-30
IL308542A (en) 2024-01-01
EP4346773C0 (en) 2025-07-02
US12485095B2 (en) 2025-12-02
EP4346773A1 (en) 2024-04-10
CN117295492A (zh) 2023-12-26
WO2022248401A1 (en) 2022-12-01

Similar Documents

Publication Publication Date Title
SK287869B6 (sk) Beta-carboline pharmaceutical compositions
CZ298499B6 (cs) Oxykodonová léková dávková forma s rízeným uvolnováním
KR20040065307A (ko) 셀레코시브 조성물
EA029096B1 (ru) Твердая лекарственная форма для перорального введения, содержащая метилналтрексон
KR102598782B1 (ko) 알펠리십을 포함하는 제약 조성물
WO2008072534A1 (ja) マンニトール又は乳糖を含有する固形製剤
US20260076908A1 (en) Plurality of tasquinimod particles and use thereof
RS62136B1 (sr) Kristalne tozilatne soli selektivnog inhibitora pi3k delta za upotrebu u farmaceutskim formulacijama
JP2023027312A (ja) ５－クロロ－ｎ４－［２－（ジメチルホスホリル）フェニル］－ｎ２－｛２－メトキシ－４－［４－（４－メチルピペラジン－１－イル）ピペリジン－１－イル］フェニル｝ピリミジン－２，４－ジアミンを含む医薬製剤
JP2021512860A (ja) 薬学的製剤
AU2014282762A1 (en) Nanoparticulate formulation comprising a TRPA1 antagonist
HK40107035B (en) A plurality of tasquinimod particles and use thereof
HK40107035A (en) A plurality of tasquinimod particles and use thereof
CN118766862A (zh) 一种贝派度酸速释片及其制备方法
JP2011246478A (ja) テルカゲパントカリウムの固形投与製剤
JP2013503876A (ja) インジブリンに関する薬学的組成物
US11701362B2 (en) Compositions and methods of use of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1- methylcyclohexane-1-carboxamide
WO2026032974A1 (en) Formulation of linaprazan glurate
TW202612693A (zh) Glp-1受體激動劑的口服藥物組合物及其製備方法
CN119060046A (zh) 含有格拉匹纶盐酸盐的药物制剂及其制备方法
TW202602438A (zh) 藥物成分、劑型及其製備及使用方法
EA040951B1 (ru) Лекарственные формы цис-4-[2-{[(3s,4r)-3-фтороксан-4-ил]амино}-8-(2,4,6-трихлоранилино)-9н-пурин-9-ил]-1-метилциклогексан-1-карбоксамида и их применение в способе лечения рака
WO2019030773A1 (en) DICLOFENAC COMPOSITIONS WITH LOW DOSE
CN112770731A (zh) 以4’-硫代核苷类化合物为活性成分的口服药物组合物、其制备方法及其用途
WO2017073738A1 (ja) フェキソフェナジンを有効成分とする錠剤

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250513

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250513

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260511

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260511

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20260521

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20260521

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260521

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260622

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260625

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260625

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260625

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260625

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260625